



News Release

SUVN-G3031 for Cognition in Alzheimer's Disease commenced Phase 1 Clinical Trial in USA under US-IND 123179

HYDERABAD, INDIA (Nov 03, 2014) – Suven Life Sciences today informed that their NCE **SUVN-3031** has commenced **Phase 1 clinical trial in USA**. **SUVN-G3031** – A potent, selective, brain penetrant and orally active Histamine H3 antagonist for the treatment of cognitive dysfunction associated with Alzheimer's Disease / Schizophrenia has completed all the pre-clinical, safety and early toxicological studies, GLP toxicological studies and was submitted for **Investigational New Drug Application {IND}** to conduct Phase 1 clinical trial with the **indication for Cognition in Alzheimer's Disease** under 505(1) of the Federal Food, Drug and Cosmetic Act (FDCA) which was assigned an **IND number 123179**.

Based on the IND **"A Single Center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the safety, Tolerability, and Pharmacokinetics of SUVN-G3031 after Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects"** for Cognition in Alzheimer's Disease is underway in USA

"We are very pleased that the second compound from our pipeline of molecules in CNS has moved into clinical trial that is being developed for cognitive disorders in Alzheimer's and Schizophrenia with high unmet medical need which has huge market potential globally" says Venkat Jasti, CEO of Suven.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. The Company has eleven (11) **internally-discovered** therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, major depressive disorder (MDD), Huntington's disease, Parkinson's disease and obesity in addition to this **Phase 1 developmental candidate SUVN-G301** and **Phase 2 a (PoC) ready SUVN-502** for **Alzheimer's disease and Schizophrenia**.

For more information please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;